A. Kenwright

IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE Study (NCT00106522)

M.A. Karsdal, Georg Schett, Paul Emery et al. · Seminars in Arthritis and Rheumatism · 2012 · 109 citations

Medicine, Immunology, Pharmacology +17

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study

Paul D. Miller, Robert R. Recker, J.-Y. Reginster et al. · Osteoporosis International · 2011 · 60 citations

Pharmacy, Pharmacotherapy, Oral Medicine In Older Adults +1

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension

Gerolamo Bianchi, E. J. Czerwiński, A. Kenwright et al. · Osteoporosis International · 2011 · 54 citations

Medicine, Endocrinology, Pharmacotherapy +9

Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis

J Wang, Aruna T. Bansal, M. Martin et al. · The Pharmacogenomics Journal · 2012 · 50 citations · Full text

Life Sciences, Genetics, Immunology +17

Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS)

Rueshandra Roosenhoff, Vaughan Reed, A. Kenwright et al. · Clinical Infectious Diseases · 2019 · 30 citations · Full text

Life Sciences, Infectious Diseases, Pediatrics +17